DLBCL化疗耐药与细胞因子IL-6、IL-10水平的相关性(1)
 |
| 第1页 |
参见附件。
[摘要] 目的 通过检测弥漫大B细胞淋巴瘤(DLBCL)患者治疗前、后血清细胞因子白介素(IL)-6、IL-10的水平变化，探讨IL-6、IL-10的表达水平与DLBCL化疗耐药的相关性。 方法 将40例确诊的DLBCL患者按对化疗的敏感性分为两组(化疗耐药组及化疗敏感组)各20例，选择同期20例健康人作为对照组，用ELISA法测定DLBCL患者各阶段及对照组血清IL-6、IL-10的水平。 结果 化疗耐药组治疗前的血清中IL-6、IL-10表达水平均明显高于化疗敏感组和对照组(均P < 0.05)，治疗缓解后明显低于治疗前(P < 0.05)；DLBCL复发耐药时，患者血清中的IL-6、IL-10表达水平又高于缓解时水平(均P < 0.05)。 结论 血清中细胞因子IL-6、IL-10的表达可预测DLBCL的疗效，可能是DLBCL耐药的相关指标。
[关键词] 弥漫大B细胞淋巴瘤；细胞因子；白细胞介素-6；白细胞介素-10；细胞耐药
[中图分类号] R733 [文献标识码] C [文章编号] 1673-7210(2012)08(c)-0154-02
Correlation between the chemotherapy resistance of diffuse large B-cell lymphoma and cytokines IL-6 and IL-10
WANG Wenxia1 WANG Bin1 LIU Xinhong2
1.Department of Hematology and Oncology, the People′s Hospital of Linqu County, Shandong Province, Linqu 262600, China; 2.Department of Radiation Oncology, the People′s Hospital of Linqu County, Shandong Province, Linqu 262600, China
[Abstract] Objective To explore the relationship between the expression of serum cytokines IL-6, IL-10 and chemotherapy resistance in patients with diffuse large B-cell lymphoma (DLBCL) by monitoring the level of serum cytokines IL-6, IL-10. Methods 40 cases which diagnosed as DLBCL were enrolled, according to the sensitivity to the chemotherapy, they were divided into two groups (chemotherapy resistant group and chemotherapy sensitive group), and 20 cases in each group, another 20 cases of healthy individuals were enrolled as the control group. The levels of serum cytokines IL-6，IL-10 at different stage in DLBCL patients and normal control group were detected by ELISA. Results The levels of serum cytokines IL-6, IL-10 in chemotherapy resistant group before therapy was all higer than chemotherapy sensitive group and control group (all P < 0 ......
您现在查看是摘要介绍页，详见PDF附件(2089kb)。